Skip to main content

JHOP - June 2023 Vol 13, No 3

ASCO 2023 Highlights

Original Research

Practical Issues in Pharmacy Management

Letters to the Editor

ASCO 2023 Highlights

ASCO 2023 Highlights

Zanidatamab Plus Docetaxel Shows Promising Antitumor Activity in Advanced HER2-Positive Breast Cancer

ASCO 2023 Highlights

Prolonged Effectiveness With Tucatinib Plus Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

ASCO 2023 Highlights

Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer

ASCO 2023 Highlights

Dalpiciclib Plus Pyrotinib Prolongs Survival in Patients With HER2-Positive Advanced Breast Cancer

ASCO 2023 Highlights

Neratinib Plus Trastuzumab Emtansine in Patients With HER2-Positive Breast Cancer and Molecular Residual Disease

ASCO 2023 Highlights

Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastases in Patients With Triple-Negative or HER2-Positive Breast Cancer

ASCO 2023 Highlights

Strong Antitumor Activity With Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer

ASCO 2023 Highlights

Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab to Find Chemotherapy-Free Treatment Combination Regimens for HER2-Positive Breast Cancer

ASCO 2023 Highlights

Dalpiciclib Plus Pyrotinib and Endocrine Therapy Shows Promising Antitumor Activity in ER-Positive, HER2-Positive Metastatic Breast Cancer

ASCO 2023 Highlights

Preclinical and Early Clinical Data Show Promising Antitumor Activity With the HER2 Inhibitor ZN-1041 in Patients With Breast Cancer and Brain Metastases

Editorial, Letters to the Editor, Infusion Issues, Adverse Events

JHOP Editorial Board Member, Readers, and Author Interact - Optimizing the Administration of Daratumumab

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Dr Soefje is Director, Pharmacy Cancer Care, Mayo Clinic, Rochester, MN.

Case Reports, PARP Inhibitors, Adverse Events, Oral Therapy, Ovarian Cancer

Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report

Lily Y. Jia, PharmD, BCOP; Brendan Sendrowski, PharmD, BCOP, DPLA; Timothy Lax, MD; Meghan Shea, MD

Original Research

Original Research, Infusion Issues, Adverse Events, Monoclonal Antibodies

Incidence of Infusion-Related Reactions With Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective Study

Sara Moran Smith, PharmD, BCOP

Original Research, Antibiotics, Infections, Adverse Events, Oncology Pharmacy Programs/Protocols

Retrospective Evaluation of Initial Empiric Double Coverage with Tobramycin in Adult Patients with Febrile Neutropenia

Amber B. Clemmons, PharmD, BCOP, FHOPA; Rachel Shelley, PharmD; Vayou Chittavong, MS, PharmD; Huimin Hu, PhD; Xianyan Chen, PhD; Joshua Eudy, PharmD, BCIDP; Andrew Chao, MD; Daniel T. Anderson, PharmD, BCIDP

Original Research, Chemotherapy, Oral Therapy, Adverse Events, VEGF Inhibitors

Stopping Oral Chemotherapy Agents With a High Bleeding Risk Before and After Minor Surgical Procedures

Dennis Marjoncu, PharmD, BCOP; Jenna Carmichael, PharmD, BCOP; Benjamin J. Andrick, PharmD, BCOP; Jacqueline Oxenberg, DO, FACS, FACOS

Practical Issues in Pharmacy Management

Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Chemotherapy, Technology

Clinical and Financial Impacts of an Ambulatory Oncology Pharmacist–Based Intravenous Chemotherapy Education and Follow-Up Program

Grant W. Lee, PharmD, BCOP; Joseen J. Chundamala, PharmD; Kerri L. Monahan, PharmD; Judy J. Cho, PharmD; Lydia J. Berry, RPh, PharmD; Christine G. Cambareri, PharmD, BCOP, CSP

FDA Updates

Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

FDA Updates

Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

FDA Updates

Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

FDA Updates

Omisirge FDA Approved for Patients With Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection

FDA Updates

Padcev Plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma

Letters to the Editor

Letters to the Editor, Editorial

JHOP Editorial Board Member, Readers, and Author Interact - Comment on Kye et al (April 2023), Authors’ Response